MAXON
Today MAXON announces the immediate availability of Cinema 4D Release 17 (R17), the newest version of its leading 3D software solution for motion graphics, visual effects, visualization and rendering. With outstanding new features for modeling, sculpting, animation and rendering, this new release will help users achieve an even more efficient workflow. The new Take System offers functions above and beyond those of any conventional render layer system and the Houdini Engine connectivity, the versatile Color Chooser and updated import and export functions with new data exchange features all combine to dramatically increase production pipeline performance. Innovative sculpting functions, expanded motion tracking features and completely reworked spline tools enhance the design process for modeling, sculpting and animation for even better results. The complete list of new functions in Cinema 4D R17 is available here .
MAXON Cinema 4D R17 will make its European debut at the IBC 2015, which will take place from September 11 – 15, 2015 at the RAI Convention Center in Amsterdam. MAXON will be in hall 7, booth No. 7.K30.
What professionals are saying about Cinema 4D R17:
Numerous 3D professionals have already thoroughly tested R17 and have shared their experiences in the following screencasts:
Cineversity‘s Cinema 4D R17 Round-up
Thanassis Potzantis R17 Workflow Presentation (Siggraph 2015)
‘11 Small Things You Will Love in Cinema 4D R17’ by Orestis Konstantinides
Tutorials and Overviews on new Features in Cinema 4D R17 by Sean Frangella
Pricing, availability and upgrades
Cinema 4D Release 17 is available at MAXON or its authorized dealers. MAXON Service Agreement customers whose MSA was active as of September 2, 2015 will be upgraded automatically. Cinema 4D Release 17 is available for Windows and OS X. Details about minimum system requirements can be found at the MAXON website.
Image material and additional information about MAXON Cinema 4D R17
Screenshots: maxonexchange.de/pr/Cinema_4D_R17/Cinema_4D_R17_Software_Screenshots.zip
Pack shots: maxonexchange.de/pr/Cinema_4D_R17/Cinema_4D_R17_Packshots.zip
Renderings: maxonexchange.de/pr/Cinema_4D_R17/Cinema_4D_R17_Artworks_RGB_CMYK.zip
R17 Website: http://www.maxon.net/products/new-in-cinema-4d-R17/
All trademarks contained herein are the property of their respective owners.
About MAXON
Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group .
MAXON Web Resources
Website: www.maxon.net
Facebook: https://www.facebook.com/maxon3d
Twitter: https://twitter.com/maxon3d
YouTube: http://www.youtube.com/user/MaxonC4D
LinkedIn: http://www.linkedin.com/company/791366
Google+: https://plus.google.com/116159295936876913625/posts
View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005692/en/
Contact:
MAXON
Bärbel Buck
+49 6172 5906643
press_de@maxon.net
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum